MedTrace Logo

The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

NCT06084585 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-10-16

No results posted yet for this study

Summary

The goal of this three arms, randomized, double-blind controlled interventional study is to evaluate the efficacy of Amway uric acid lowering product improving hyperuricemia in patients aged 18 and 65 years old. The main question it aims to answer is:

\- whether the serum uric acid level of patients with hyperuricemia could be significantly lowered after 3 months intervention with Amway uric acid lowering product

180 eligible participants will be enrolled in one study site and randomized to three study groups (two product group and one placebo group), who will consume the assigned products for 3 months and be arranged to 3 site visits. All relevant clinical data will be captured and recorded into CTMS (Clinical Trial Management System) for statistical analysis and reporting.

Researchers will compare the three study groups to conclude how Amway uric acid lowering product will improve hyperuricemia.

Conditions

  • Hyperuricemia

Interventions

DIETARY_SUPPLEMENT

Study Product A (High-dose 2X)

participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months

DIETARY_SUPPLEMENT

Study Product B (Low-dose X)

participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months

DIETARY_SUPPLEMENT

Placebo

participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months

Sponsors & Collaborators

  • Amway (China) R&D Center

    lead INDUSTRY

Principal Investigators

  • Dan Cao, MD · Jinhua Wenrong Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2024-02-28
Completion
2024-03-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06084585 on ClinicalTrials.gov